Current Duke Appointments & Affiliations
Associate Professor of Urology
·
2022 - Present
Urology,
Clinical Science Departments
Member of the Duke Cancer Institute
·
2021 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
The first United States prospective trial using the Hugo™ robot-assisted surgery system.
Journal article BJU Int · July 2026 OBJECTIVE: To describe the safety and effectiveness of the Hugo™ robot-assisted surgery (RAS) system (Medtronic, Minneapolis, MN, USA) when used for three urological procedures. PATIENTS AND METHODS: The Expand URO (ClinicalTrials.gov identifier: NCT056964 ... Full text Link to item CiteOutcomes of consolidative surgery following enfortumab vedotin plus pembrolizumab for advanced urothelial cancer: A real-world experience.
Journal article Urol Oncol · June 2026 INTRODUCTION: Enfortumab vedotin plus pembrolizumab (EVP) has emerged as frontline treatment for patients with advanced urothelial carcinoma. Consolidative surgery can be offered to select patients with surgically resectable disease following EVP; however, ... Full text Link to item CiteEvaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis.
Journal article Urol Oncol · June 2026 INTRODUCTION: Emerging evidence suggests that metachronous non-muscle invasive bladder cancer (m-NMIBC) recurrence after prior upper tract urothelial carcinoma (UTUC) treatment is distinct from primary NMIBC (p-NMIBC). Correspondingly, their disease trajec ... Full text Link to item CiteRecent Grants
NWU22-12-01 A PHASE 2 PLACEBO-CONTROLLED TRIAL OF UROLITHIN A SUPPLEMENTATION IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY
Clinical TrialPrincipal Investigator · Awarded by Northwestern University · 2024 - 2031Phase 1, open label, dose escalation and dose expansion study to eval the safety, tolerability, pharmacokinetics and antitumor activity of PF-08052667 as a single agent and in comb therapy in participants 18 years of age and older with bladder cancer
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2026 - 2031TYRA-300
Clinical TrialPrincipal Investigator · Awarded by Tyra Biosciences, Inc. · 2026 - 2031View All Grants
Education
Rush University, Medical College ·
2006
M.D.
University of Illinois ·
1996
B.S.